EMAIL THIS PAGE TO A FRIEND

Biopolymers

Chemical synthesis of a polypeptide backbone derived from the primary sequence of the cancer protein NY-ESO-1 enabled by kinetically controlled ligation and pseudoprolines.


PMID 25656702

Abstract

The cancer protein NY-ESO-1 has been shown to be one of the most promising vaccine candidates although little is known about its cellular function. Using a chemical protein strategy, the 180 amino acid polypeptide, tagged with an arginine solubilizing tail, was assembled in a convergent manner from four unprotected peptide α-thioester peptide building blocks and one cysteinyl polypeptide, which were in turn prepared by Boc and Fmoc solid phase peptide synthesis (SPPS) respectively. To facilitate the assembly by ligation chemistries, non-native cysteines were introduced as chemical handles into the polypeptide fragments; pseudoproline dipeptides and microwave assisted Fmoc SPPS were crucial techniques to prepare the challenging hydrophobic C-terminal fragment. Three sequential kinetically controlled ligations, which exploited the reactivity between peptide arylthioesters and peptide alkylthioesters, were then used in order to assemble the more tractable N-terminal region of NY-ESO-1. The ensuing 147 residue polypeptide thioester then underwent successful final native chemical ligation with the very hydrophobic C-terminal polypeptide bearing an N-terminal cysteine affording the 186 residue polypeptide as an advanced intermediate en route to the native NY-ESO-1 protein.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

157260
1-Hydroxybenzotriazole hydrate, wetted with not less than 14 wt. % water, 97%
C6H5N3O · xH2O
711489
1-Hydroxybenzotriazole hydrate, wetted with not less than 20 wt. % water, 97%
C6H5N3O · xH2O
653152
4-Mercaptophenylacetic acid, 97%
C8H8O2S
D125407
DIC, 99%
C7H14N2
F8916
Fmoc-Arg(Pbf)-OH
C34H40N4O7S
47349
Fmoc-Arg(Pbf)-OH, ≥98.0% (HPLC)
C34H40N4O7S
F1393
Fmoc-Asn(Trt)-OH, ~95%
C38H32N2O5
47672
Fmoc-Asn(Trt)-OH, ≥97.0% (sum of enantiomers, HPLC)
C38H32N2O5
47674
Fmoc-Gln(Trt)-OH, ≥98.0% (HPLC)
C39H34N2O5
47625
Fmoc-Glu(OtBu)-OH, ≥98.0% (HPLC)
C24H27NO6
47639
Fmoc-His(Trt)-OH, ≥98.0% (sum of enantiomers, HPLC)
C40H33N3O4
47624
Fmoc-Lys(Boc)-OH, ≥98.0% (HPLC)
C26H32N2O6
CDS003509
fmoc-met(o)-oh, AldrichCPR
C20H21NO5S
47561
Fmoc-Trp(Boc)-OH, ≥97.0% (HPLC)
C31H30N2O6
445460
HATU, 97%
C10H15F6N6OP
M79204
N-Methylpyrrolidine, 97%
C5H11N
233781
Triisopropylsilane, 98%
C9H22Si
68957
Tris(2-carboxyethyl)phosphine hydrochloride, BioUltra, for electrophoresis, SDS-PAGE tested
C9H15O6P · HCl
C4706
Tris(2-carboxyethyl)phosphine hydrochloride, powder, ≥98%
C9H15O6P · HCl
75259
Tris(2-carboxyethyl)phosphine hydrochloride, BioUltra, ≥98% (NMR)
C9H15O6P · HCl
646547
Tris(2-carboxyethyl)phosphine hydrochloride solution, 0.5 M, pH 7.0(aqueous solution; pH was adjusted with ammonium hydroxide)
C9H15O6P · HCl